Development and validation of the lupus impact tracker: A patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1542-1550

  Jolly, Meenakshi ^a   Garris, Cindy P ^b   Mikolaitis, Rachel A ^a   Jhingran, Priti M ^b   Dennis, Greg ^c   Wallace, Daniel J ^d   Clarke, Ann ^e   Dooley, Mary Anne ^f   Parke, Ann ^g   Strand, Vibeke ^h   Alárcon, Graciela S ⁱ   Kosinski, Mark ^j  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Pharmaceutical Product Development   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF CONNECTICUT   (United States)

^h University of Alabama ^*  (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j QualityMetric Incorporated   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CONFIRMATORY FACTOR ANALYSIS; CONVERGENT VALIDITY; DISCRIMINANT VALIDITY; DISEASE ACTIVITY; FACTORIAL ANALYSIS; FEMALE; HUMAN; INFORMATION PROCESSING; INTERNAL CONSISTENCY; LUPUS IMPACT TRACKER; MALE; REGRESSION ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TEST RETEST RELIABILITY; CLINICAL TRIAL; COST OF ILLNESS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; QUESTIONNAIRE; REPRODUCIBILITY; SICKNESS IMPACT PROFILE; UNITED STATES; VALIDATION STUDY;

ADULT; COST OF ILLNESS; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOCUS GROUPS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUESTIONNAIRES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; UNITED STATES;

EID: 84908506069     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22349     Document Type: Article

References (31)

1. Lupus Foundation of America. 2010. URL: http://www.lupus.org/newsite/index.html.
2. Balluz L, Philen R, Ortega L, Rosales C, Brock J, Barr D, et al. Investigation of systematic lupus erythematosus in Nogales, Arizona. Am J Epidemiol 2001;154:1029-36.
3. Naleway AL, Davis ME, Greenlee RT, Wilson DA, McCarty DJ. Epidemiology of systematic lupus erythematosus in rural Wisconsin. Lupus 2005;14:862-6.
4. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007;36:115-22.
5. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005;32:1706-8.
6. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
7. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:541-7.
8. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
9. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
11. Grootscholten C, Ligtenberg G, Derksen RH, Schreurs KM, de Glas-Vos JW, Hagen EC, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res 2003;12:635-44.
12. Moses N, Wiggers J, Nicholas C, Cockburn J. Development and psychometric analysis of the systemic lupus erythematosus needs questionnaire (SLENQ). Qual Life Res 2007;16:461-6.
13. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280-6.
14. Peralta-Ramirez M, Verdejo A, Munoz M, Sabio J, Jimenez-Alonso J, Perez-Garcia M. Lupus Symptoms Inventory (LSI): development and validation of a self-evaluation inventory of the subjective symptoms of systemic lupus erythematosus. J Clin Psychol Med Settings 2007;14:344-50.
15. Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012;42:56-65.
16. Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford) 2005;44:1267-76.
17. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a diseasespecific health-related quality of life measure, the LupusQOL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9.
18. Doward L, McKenna D, Whalley D. The development of the L-QOL: a quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009;68:196-200.
19. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
20. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
21. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
22. Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P, et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.
23. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
24. Bentler PM, Bonett DG. Signnificance tests and goodness of fit in the analysis of covariance structures. Psychol Bull 1980; 88:588-606.
25. Bentler PM. Comparative fit indexes in structural models. Psychol Bull 1990;107:238-46.
26. Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika 1973;38:1-10.
27. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling 1999;6:1-55.
28. Kerlinger FN. Foundations of behavioral research. New York: Holt, Rinehart and Winston; 1973.
29. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
30. Stamm TA, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G, et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007; 57:1287-95.
31. Ware JE Jr., Kosinski M, Keller SD. A 12-item short-form health survey. Med Care 1996;34:220-33.